Bibliography
- Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2010. Available from http://www.goldcopd.org; accessed in March 2011
- Anthonisen NR, Connett JE, Kiley JP, Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272:1497-505
- Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002;166:675-9
- Murray RP, Connett JE, Rand CS, Persistence of the effect of the Lung Health Study (LHS) smoking intervention over eleven years. Prev Med 2002;35:314-19
- Chantix® (varenicline) Tablets. Highlights of prescribing information
- Gonzales D, Jorenby DE, Brandon TH, Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo. Addiction 2011;105:2002-13
- Jorenby DE, Hays JT, Rigotti NA, Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56-63
- Tashkin DP, Rennard S, Hays JT, Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 2011;139:591-9